Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Form 8.3 - The Vanguard Group, Inc.: Horizon Discovery Group plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Discovery Group plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Discovery Group plc
eqs_en 
0 03.11.20
Hardman & Co Research: Tissue Regenix (TRX): Funded through to profitability
Hardman & Co Research: Tissue Regenix (TRX): Funded through to profitability
Hardman & Co Research: Tissue Regenix (TRX): Funded through to profitability
eqs_en 
0 07.10.20
Edison Investment Research Limited: Oxford Biomedica (OXB): Vector innovation key to cell and gene evolution
Edison Investment Research Limited: Oxford Biomedica (OXB): Vector innovation key to cell and gene evolution
Edison Investment Research Limited: Oxford Biomedica (OXB): Vector innovation key to cell and gene evolution
eqs_en 
0 05.10.20
Hardman & Co Research: Diurnal (DNL): And then there were three
Hardman & Co Research: Diurnal (DNL): And then there were three
Hardman & Co Research: Diurnal (DNL): And then there were three
eqs_en 
0 30.09.20
Hardman & Co Research: Diurnal Group (DNL): Closely watching the regulators
Hardman & Co Research: Diurnal Group (DNL): Closely watching the regulators
Hardman & Co Research: Diurnal Group (DNL): Closely watching the regulators
eqs_en 
0 17.09.20
Hardman & Co Research: Diurnal Group (DNL): Q&A with Dr Martin Hall
Hardman & Co Research: Diurnal Group (DNL): Q&A with Dr Martin Hall
Hardman & Co Research: Diurnal Group (DNL): Q&A with Dr Martin Hall
eqs_en 
0 20.08.20
Hardman & Co Research: Diurnal Group (DNL): Flow of regulatory approvals
Hardman & Co Research: Diurnal Group (DNL): Flow of regulatory approvals
Hardman & Co Research: Diurnal Group (DNL): Flow of regulatory approvals
eqs_en 
0 13.08.20
Hardman & Co Research: Allergy Therapeutics (AGY): Record sales and a COVID-19 wildcard
Hardman & Co Research: Allergy Therapeutics (AGY): Record sales and a COVID-19 wildcard
Hardman & Co Research: Allergy Therapeutics (AGY): Record sales and a COVID-19 wildcard
eqs_en 
0 20.07.20
Form 8.3 - Link Fund Solutions Ltd: Midatech Pharma Plc (Replacement)
Form 8.3 - Link Fund Solutions Ltd: Midatech Pharma Plc (Replacement)
Form 8.3 - Link Fund Solutions Ltd: Midatech Pharma Plc (Replacement)
eqs_en 
0 11.06.20
Edison Inv Research Limited: Edison issues flash on Ergomed (ERGO)
Edison Inv Research Limited: Edison issues flash on Ergomed (ERGO)
Edison Inv Research Limited: Edison issues flash on Ergomed (ERGO)
eqs_en 
0 10.06.20
Form 8.3 - Link Fund Solutions Ltd: Midatech Pharma PLC
Form 8.3 - Link Fund Solutions Ltd: Midatech Pharma PLC
Form 8.3 - Link Fund Solutions Ltd: Midatech Pharma PLC
eqs_en 
0 09.06.20
Form 8.3 - Link Fund Solutions Ltd: Midatech Pharma Plc
Form 8.3 - Link Fund Solutions Ltd: Midatech Pharma Plc
Form 8.3 - Link Fund Solutions Ltd: Midatech Pharma Plc
eqs_en 
0 22.04.20
Edison Investment Research Limited: Edison issues update on Silence Therapeutics (SLN)
Edison Investment Research Limited: Edison issues update on Silence Therapeutics (SLN)
Edison Investment Research Limited: Edison issues update on Silence Therapeutics (SLN)
eqs_en 
0 17.04.20
Hardman & Co Research: Diurnal (DNL): $52.5m US deal strengthens balance sheet further
Hardman & Co Research: Diurnal (DNL): $52.5m US deal strengthens balance sheet further
Hardman & Co Research: Diurnal (DNL): $52.5m US deal strengthens balance sheet further
eqs_en 
0 30.03.20
Edison Investment Research Limited: Edison issues update on Silence Therapeutics (SLN)
Edison Investment Research Limited: Edison issues update on Silence Therapeutics (SLN)
Edison Investment Research Limited: Edison issues update on Silence Therapeutics (SLN)
eqs_en 
0 25.03.20
Edison Investment Research Limited: Edison issues initiation on Ergomed (ERGO)
Edison Investment Research Limited: Edison issues initiation on Ergomed (ERGO)
Edison Investment Research Limited: Edison issues initiation on Ergomed (ERGO)
eqs_en 
0 25.03.20
Hardman & Co Research: Allergy Therapeutics (AGY): Consistent first-half revenue growth
Hardman & Co Research: Allergy Therapeutics (AGY): Consistent first-half revenue growth
Hardman & Co Research: Allergy Therapeutics (AGY): Consistent first-half revenue growth
eqs_en 
0 09.03.20
Form 8.3 - The Vanguard Group, Inc.: NMC Health plc
Form 8.3 - The Vanguard Group, Inc.: NMC Health plc
Form 8.3 - The Vanguard Group, Inc.: NMC Health plc
eqs_en 
0 28.02.20
Hardman & Co Research: Diurnal (DNL): . and more to come (news flow)
Hardman & Co Research: Diurnal (DNL): . and more to come (news flow)
Hardman & Co Research: Diurnal (DNL): . and more to come (news flow)
eqs_en 
0 28.02.20
Form 8.3 - The Vanguard Group, Inc.: NMC Health plc
Form 8.3 - The Vanguard Group, Inc.: NMC Health plc
Form 8.3 - The Vanguard Group, Inc.: NMC Health plc
eqs_en 
0 27.02.20
Form 8.3 - The Vanguard Group, Inc.: NMC Health plc
Form 8.3 - The Vanguard Group, Inc.: NMC Health plc
Form 8.3 - The Vanguard Group, Inc.: NMC Health plc
eqs_en 
0 26.02.20
Form 8.3 - The Vanguard Group, Inc.: NMC Health plc
Form 8.3 - The Vanguard Group, Inc.: NMC Health plc
Form 8.3 - The Vanguard Group, Inc.: NMC Health plc
eqs_en 
0 25.02.20
Form 8.3 - The Vanguard Group, Inc.: NMC Health plc
Form 8.3 - The Vanguard Group, Inc.: NMC Health plc
Form 8.3 - The Vanguard Group, Inc.: NMC Health plc
eqs_en 
0 24.02.20
Form 8.3 - The Vanguard Group, Inc.: NMC Health plc
Form 8.3 - The Vanguard Group, Inc.: NMC Health plc
Form 8.3 - The Vanguard Group, Inc.: NMC Health plc
eqs_en 
0 21.02.20
Form 8.3 - The Vanguard Group, Inc.: NMC Health plc
Form 8.3 - The Vanguard Group, Inc.: NMC Health plc
Form 8.3 - The Vanguard Group, Inc.: NMC Health plc
eqs_en 
0 19.02.20